Chardan Capital reiterated their buy rating on shares of Allurion Technologies (NYSE:ALUR - Free Report) in a research note released on Wednesday morning, Benzinga reports. Chardan Capital currently has a $5.00 target price on the stock.
Separately, Jefferies Financial Group initiated coverage on shares of Allurion Technologies in a research report on Friday, February 9th. They set a buy rating and a $5.00 target price on the stock.
Read Our Latest Report on ALUR
Allurion Technologies Stock Down 10.4 %
ALUR traded down $0.22 during midday trading on Wednesday, hitting $1.89. 127,602 shares of the company were exchanged, compared to its average volume of 695,762. The firm's 50 day moving average price is $2.17 and its 200-day moving average price is $3.01. Allurion Technologies has a 1-year low of $1.56 and a 1-year high of $9.00.
Allurion Technologies (NYSE:ALUR - Get Free Report) last posted its quarterly earnings data on Tuesday, May 14th. The company reported $0.11 EPS for the quarter. The company had revenue of $9.39 million during the quarter. On average, analysts anticipate that Allurion Technologies will post -0.87 EPS for the current year.
Hedge Funds Weigh In On Allurion Technologies
Large investors have recently bought and sold shares of the stock. Alpine Global Management LLC purchased a new position in shares of Allurion Technologies in the 3rd quarter worth about $97,000. Accredited Investors Inc. bought a new stake in Allurion Technologies in the third quarter worth about $161,000. Finally, RTW Investments LP bought a new stake in Allurion Technologies in the third quarter worth about $14,868,000. 21.39% of the stock is currently owned by institutional investors.
Allurion Technologies Company Profile
(
Get Free Report)
Allurion Technologies Inc focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite.
Read More
Before you consider Allurion Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Allurion Technologies wasn't on the list.
While Allurion Technologies currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
